Tag Archives: NIMH

Harvard Expert Ties Mental Illness “Epidemic” to Big Pharma’s Agenda

For any mental illness or passing mood swing that may trouble a person, the Diagnostic and Statistical Manual of Mental Disorders — better known as the DSM — has a label and a code. Recurring bad dreams? That may be a Nightmare Disorder, or 307.47. Narcolepsy uses the same digits in a different order: 347.00. Fancy feather ticklers? That sounds like Fetishism, or 302.81. Then there’s the ultimate catch-all for vague sadness or uneasiness, General Anxiety Disorder, or 300.02. That’s a label almost everyone can lay claim to.Drug companies are particularly eager to win over faculty psychiatrists at prestigious academic medical centers. Called “key opinion leaders” (KOLs) by the industry, these are the people who through their writing and teaching influence how mental illness will be diagnosed and treated. They also publish much of the clinical research on drugs and, most importantly, largely determine the content of the DSM. In a sense, they are the best sales force the industry could have, and are worth every cent spent on them. Of the 170 contributors to the current version of the DSM (the DSM-IV-TR), almost all of whom would be described as KOLs, ninety-five had financial ties to drug companies, including all of the contributors to the sections on mood disorders and schizophrenia.

Pharma-Funded Psychiatrists Behind Bogus Child ‘Bi-Polar’ Epidemic- Disciplined for Conflicts of Interest

The primary promoters–inventors, one might say– of diagnosing children with “bipolar” disorder, who for over a decade, aggressively promoted the biopolar diagnosis and use of antipsychotics in children, were disciplined by Harvard University and its affiliated Massachusetts General Hospital.

An investigation, prompted by Sen. Charles Grassely, was conducted by Harvard University-affiliated Massachusetts General Hospital. It concluded (earlier this month) that psychiatrist Joseph Biederman and two of his proteges, Thomas Spencer and Timothy Wilens -each of who failed to disclose millions of dollars they had each received from the makers of antipsychotics, the drugs they promoted for the treatment of bipolar in children–had indeed violated the University’s/ and hospital’s conflict of interest reporting standards. The companies that paid them millions include: Eli Lilly, Johnson & Johnson, Pfizer, GlaxoSmithKline and Bristol-Myers Squibb.

The Voices Inside Their Heads – Gail Hornstein’s Approach To Understanding Madness

The term “mental illness” is heavily charged, politicized, and ambiguous. I prefer to talk about “anomalous experiences,” “extreme emotions,” and “emotional distress.” The main reason I don’t use medical language is that people who are suffering often don’t find it very helpful. No one experiences “schizophrenia” — that’s just a technical name for a lot of complicated feelings.

People who have been taught that “mental illnesses are brain diseases” see psychiatric patients as dangerous and unlikely to recover. And those in crisis are often understandably reluctant to consult mental-health professionals, because the stigma of mental illness is so severe: it’s possible to lose your job, your home, and your family as a consequence of being diagnosed with a mental illness. In cultures that take a social view of emotional distress, by contrast, people more readily seek help because they aren’t as likely to be ostracized and are assumed to be capable of full recovery.

5 Myths About Depression Treatments

Myth 1: Antidepressants Are More Effective than Placebos
Myth 2: If the First Antidepressant Fails, Another Antidepressant Will Likely Succeed
Myth 3: Electroconvulsive Treatment (ECT) is an Effective Last Resort
Myth 4: Cognitive Behavior Therapy (CBT) is the Best Psychotherapy for Depression
Myth 5: No Treatment for Depression Works

Confronting Bigots Intolerant of Alternative Mental Health Treatment

A long-term outcome study of schizophrenic patients who were treated with and without psychiatric drugs was published in 2007 in the Journal of Nervous and Mental Disorders. Funded by the National Institute of Mental Health, research psychologist Martin Harrow, at the University of Illinois College of Medicine, discovered that after 4.5 years, 39 percent of the non-medicated group were “in recovery” and 60 percent had jobs. In contrast, during that same time period, the condition of the medicated patients worsened, with only six percent in recovery and few holding jobs. At the fifteen-year follow-up, among the non-drug group, only 28 percent suffered from any psychotic symptoms; in contrast, among the medicated group, 64 were actively psychotic.